JA
Jazz Pharmaceuticals plc
JAZZ · NASDAQ
$241.31 +1.39% (+$3.30)
1M -3.19%
Market Cap $15.2B
P/E Ratio 16.11x
Div. Yield -
ROE 21.37%
Bulios Fair Price
$241.16
0.1% downside
Current Price
$241.31
Undervalued Fair Value Overvalued
According to Bulios Fair Price, JAZZ is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
75 /100
Cheap P/E 16.11x
EV/EBITDA 12.16x
P/FCF 9.83x
Growth
68 /100
Growing Rev. growth 5.26%
FCF growth 18.79%
Book val. growth 11.86%
Profitability
100 /100
Strong Gross margin 84.67%
Net margin 20.45%
FCF margin 33.52%
Quality
84 /100
Excellent ROIC 18.70%
ROE 21.37%
Asset turnover 0.42x
Debt
64 /100
Moderate Debt/Equity 0.92x
Current ratio 1.78x
Net debt/EBITDA 1.89x
Stability
39 /100
Moderate Beta 0.32x
Rev. volatility 0.75%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about JAZZ
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Renee D. Gala
Employees
2,890
Headquarters
Dublin
Upcoming events
04 NOV
Earnings
Upcoming earnings report